title: Manipulation of the hepcidin pathway for therapeutic purposes.
abstract: Hepcidin, the liver-produced peptide hormone, is a principal regulator of iron homeostasis. Abnormal hepcidin production has emerged as a causative factor in several common iron disorders. Hepcidin insufficiency results in iron overload in hereditary hemochromatosis and iron-loading anemias, whereas hepcidin excess causes or contributes to the development of iron-restricted anemias in inflammatory diseases, infections, some cancers and chronic kidney disease. Not surprisingly, hepcidin and related pathways have become the target for the development of novel therapeutics for iron disorders. In this review, we will summarize the strategies and development programs that have been devised for agonizing or antagonizing hepcidin and its receptor ferroportin.
authors.affiliation: enemeth@mednet.ucla.edu.
authors.forename: Eileen
authors.initials: E
authors.lastname: Fung
authors.forename: Elizabeta
authors.initials: E
authors.lastname: Nemeth
mesh_terms: D018798:Anemia, Iron-Deficiency / Q000188:drug therapy / Q000378:metabolism; D000818:Animals; D064451:Hepcidins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006706:Homeostasis / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage; D019189:Iron Metabolism Disorders / Q000188:drug therapy / Q000378:metabolism; D019190:Iron Overload / Q000188:drug therapy / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*
chemical_list: D064451:Hepcidins; D007502:Iron Chelating Agents